Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 1, Pages 6-12
Publisher
Elsevier BV
Online
2021-10-15
DOI
10.1016/j.annonc.2021.09.020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States
- (2021) Carolina Iglesias-Lopez et al. CYTOTHERAPY
- Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
- (2021) Eryn Blass et al. Nature Reviews Clinical Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation
- (2021) Ching Lam et al. CYTOTHERAPY
- Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells
- (2021) Alka Dwivedi et al. MOLECULAR CANCER THERAPEUTICS
- Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
- (2021) Martin Thelen et al. npj Precision Oncology
- Sterility Testing for Cellular Therapies: What is the Role of the Clinical Microbiology Laboratory?
- (2020) James E. T. Gebo et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Cancer cell therapies: the clinical trial landscape
- (2020) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
- (2020) Maria Castella et al. Frontiers in Immunology
- Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
- (2020) Orit Itzhaki et al. Journal for ImmunoTherapy of Cancer
- Cost of decentralized CAR T‐cell production in an academic nonprofit setting
- (2020) Tao Ran et al. INTERNATIONAL JOURNAL OF CANCER
- Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
- (2020) Valentina Bianchi et al. Frontiers in Immunology
- Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
- (2020) Michael A. Morgan et al. Frontiers in Immunology
- CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
- (2020) David C. Bishop et al. Molecular Therapy-Methods & Clinical Development
- Clinical development of CAR T cell therapy in China: 2020 update
- (2020) Jianshu Wei et al. Cellular & Molecular Immunology
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
- (2020) Kathryn M. Cappell et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
- (2020) Colby R. Maldini et al. NATURE MEDICINE
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
- (2020) Lidia Mateo et al. Genome Medicine
- Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
- (2019) Sandhya R. Panch et al. MOLECULAR THERAPY
- EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
- (2019) Giulia Detela et al. Molecular Therapy-Methods & Clinical Development
- Preservation of cell-based immunotherapies for clinical trials
- (2019) RUI LI et al. CYTOTHERAPY
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- Optimizing CAR-T Cell Manufacturing Processes During Pivotal Clinical Trials
- (2019) Seshu Tyagarajan et al. Molecular Therapy-Methods & Clinical Development
- GMP CAR-T cell production
- (2018) Adrian P. Gee BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Expediting Drug Development
- (2018) Annegret Vaggelas et al. Therapeutic Innovation & Regulatory Science
- Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study
- (2018) Magnus Pedersen et al. OncoImmunology
- Emerging Cellular Therapies for Cancer
- (2018) Sonia Guedan et al. Annual Review of Immunology
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR-T cell manufacturing: time to put it in gear
- (2017) Alexey Bersenev TRANSFUSION
- Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
- (2016) R. Andersen et al. CLINICAL CANCER RESEARCH
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More